Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.1.1.1 (alcohol dehydrogenase)
 9,284 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

MK 421, 25 mg/kg, administered daily by gavage to young spontaneously hypertensive rats (SHRs) from their 4th to 15th weeks of age almost completely inhibited genetic hypertension development. Since heart rate and cardiac index were not drug affected, prevention of genetic hypertension development was solely related to an early, potent and long-lasting limitation of the progressive increase in peripheral resistance which normally develops in SHRs during ageing. MK 421 slightly enhanced vascular responsiveness to exogenous norepinephrine and angiotensin II and reduced myocardial hypertrophy. Plasma renin concentration was increased. MK 421 slightly reduced body growth but did not affect fluid intake, urinary volume and urinary ADH, demonstrating that no water or salt retention developed. Finally, MK 421's preventive effects against genetic hypertension development persisted up to 10 weeks after treatment discontinuation.
 ...
PMID:[Prevention of the development of genetic hypertension by MK 421 in the SHR]. 628 57

The effects of bromocriptine (BRC; 20 mg X kg-1, b.i.d., orally) on genetic hypertension development (GHD), cardiovascular hemodynamics, regional vascular reactivity to vasopressor agents and biological parameters have been investigated in spontaneously hypertensive rats (SHRs) treated from their 4th to 20th weeks of age. BRC only partially opposed GHD and this was due to a limitation of the progressive increase in peripheral resistance which normally develops in SHRs with ageing since simultaneously cardiac index was not modified. Renal blood flow was increased and renal and mesenteric vascular responsiveness to norepinephrine was reduced. BRC almost completely suppressed prolactin plasma levels and slightly reduced epinephrine and norepinephrine plasma levels. Plasma Na+ and urinary volume and ADH values were not modified. The discrepancy between the favourable antihypertensive profile of BRC and its limited preventive effects against GHD remains to be elucidated.
 ...
PMID:Bromocriptine and genetic hypertension development in young spontaneously hypertensive rats. 673 76